Company Overview - Structure Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oral therapeutics for chronic diseases with high unmet need, including Type 2 diabetes, obesity, and pulmonary and cardiovascular diseases [9] - The company has a market capitalization of $5.60 billion and employs 163 people [5] - The net income for the trailing twelve months (TTM) is -$210.69 million, with a one-year price change of 212.55% as of January 12, 2026 [5] Recent Transactions - FMR LLC, a 10% owner of Structure Therapeutics, indirectly sold 52,356 shares for approximately $3.8 million on December 8, 2025 [2][3] - This sale represents the largest single open-market transaction for FMR LLC, significantly exceeding the recent median sell size of 21,997 shares [8] - Following the transaction, FMR LLC holds 471,207 shares indirectly, with a post-transaction value of approximately $33.92 million [3] Market Context - The shares were sold at a price of around $71.98 per share, which was higher than the market closing price of $69.98 on the same day [8] - Shortly after the sale, on December 11, 2025, Structure Therapeutics announced the closing of a public offering that raised approximately $748 million, indicating strong stakeholder support [12] Investment Considerations - Investors should note that FMR LLC purchased American Depositary Shares (ADS), which are fractional shares of ordinary shares offered on the U.S. stock market, allowing American investors to invest in foreign companies [10] - Holding ADS may incur occasional fees, typically ranging from 1 to 5 cents per share [11]

We recently published 8 Stocks on Jim Cramer’s Radar.  Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer's radars. Eli Lilly and Company (NYSE:LLY) is another top Cramer healthcare stock. Over the course of the year, the CNBC TV host has praised the firm’s lead in the weight loss drug industry and its manufacturing capacity. Cramer has also asserted that Eli Lilly and Company (NYSE:LLY) has a robust drug pipeline that can help the firm in non-weight-loss drug markets. However, more recen ...

New data shows significant insider sales for major Fortune 500 stocks including Nvidia, Tesla, and Fox Corp., among others, transactions that typically draw substantial interest from investors. Nvidia insiders sold more than $1 billion worth of stock from June 2024 to June 2025, with Nvidia CEO Jensen Huang selling shares worth $42 million. Fox insiders are in selling mode, with a total of $1.165 billion in insider trades and more "sells" than "buys." Tesla insiders are taking the same path, with jus ...

Retirement is complicated, and you only get one chance to do it right. Don't miss out because you didn't know what was out there. The Value Portfolio specializes in building retirement portfolios and utilizes a fact-based research strategy to identify investments. This includes extensive readings of 10Ks, analyst commentary, market reports, and investor presentations. He invests real money in the stocks he recommends. Analyst's Disclosure:I/we have a beneficial long position in the shares of NVO either thro ...